| Dr Thomas Andrew Wilkinson, PSYD | |
|
831 Highway 150 S, Evanston, WY 82930-5340 | |
| (307) 789-3464 | |
| Not Available |
| Full Name | Dr Thomas Andrew Wilkinson |
|---|---|
| Gender | Male |
| Speciality | Psychologist - Clinical |
| Location | 831 Highway 150 S, Evanston, Wyoming |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891890117 | NPI | - | NPPES |
| 497413401 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | 303824-2501 (Utah) | Secondary |
| 103TC0700X | Psychologist - Clinical | 574 (Wyoming) | Primary |
| Entity Name | State Of Wyoming |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316011562 PECOS PAC ID: 4587552583 Enrollment ID: O20040728001439 |
News Archive
Octapharma AG recently submitted its Biological License Application for octagam(R) 10% (human normal intravenous immunoglobulin, liquid) to the U.S. Food and Drug Administration (FDA) with the goal of expanding the biopharmaceutical company's U.S. immune globulin therapy portfolio by early 2010. The application was submitted for the treatment of Idiopathic Thrombocytopenic Purpura (ITP), a blood-clotting disorder that can result in excessive bruising and bleeding.
The U.S. faces a "financial crisis," in part because of spending on entitlement programs, and the "situation will become much worse as Americans age and health care costs rise," Tyler Cowen, a professor of economics at George Mason University, writes in a New York Times opinion piece.
Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients.
Researchers have identified an enzyme crucial to the malaria parasite's invasion of red blood cells, according to a study in the open-access journal, PLoS Pathogens.
Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Andrew Wilkinson, PSYD Po Box 177, Evanston, WY 82931-0177 Ph: (307) 789-3464 | Dr Thomas Andrew Wilkinson, PSYD 831 Highway 150 S, Evanston, WY 82930-5340 Ph: (307) 789-3464 |
News Archive
Octapharma AG recently submitted its Biological License Application for octagam(R) 10% (human normal intravenous immunoglobulin, liquid) to the U.S. Food and Drug Administration (FDA) with the goal of expanding the biopharmaceutical company's U.S. immune globulin therapy portfolio by early 2010. The application was submitted for the treatment of Idiopathic Thrombocytopenic Purpura (ITP), a blood-clotting disorder that can result in excessive bruising and bleeding.
The U.S. faces a "financial crisis," in part because of spending on entitlement programs, and the "situation will become much worse as Americans age and health care costs rise," Tyler Cowen, a professor of economics at George Mason University, writes in a New York Times opinion piece.
Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients.
Researchers have identified an enzyme crucial to the malaria parasite's invasion of red blood cells, according to a study in the open-access journal, PLoS Pathogens.
Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma.
› Verified 8 days ago
Dr. Pamela R Fuller, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 724 Front Street Suite 230, Evanston, WY 82930 Phone: 307-789-6773 Fax: 307-789-3244 | |
Mikaela Bernthaler, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 50 Allegiance Cir, Evanston, WY 82930 Phone: 307-789-3710 Fax: 307-789-0823 | |
Dr. Lauren Silberstein, PH.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 50 Allegiance Cir, Evanston, WY 82930 Phone: 307-789-3710 Fax: 307-789-0823 | |
Adam K Fuller, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 191 Overthrust Rd, Evanston, WY 82930 Phone: 435-631-9918 | |
Candyce Lynn Shields, PH.D Psychologist Medicare: Not Enrolled in Medicare Practice Location: 831 State Highway 150 S, Evanston, WY 82930 Phone: 307-789-3464 Fax: 307-789-7373 | |
Claire Camp, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 50 Allegiance Cir, Evanston, WY 82930 Phone: 307-789-3710 Fax: 307-789-0823 | |
Dr. Juliet L Jett, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 724 Front Street, Suite 230, Evanston, WY 82930 Phone: 307-789-6773 Fax: 307-789-3244 |